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BehaviorThe discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to
the speculation that rapamycin has ‘anti-aging’ properties. Themajor question discussed in this review iswheth-
er a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a
disease inwhich age is themajor risk factor. Rapamycin has been shown to prevent (and possibly restore in some
cases) the deﬁcit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ
and tau aggregation, restore cerebral blood ﬂow and vascularization, and reducemicroglia activation. All of these
parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has
also been shown to improve memory and reduce anxiety and depression in several other mouse models that
show cognitive deﬁcits as well as in ‘normal’mice. The current research shows the feasibility of using pharmaco-
logical agents that increase lifespan, such as those identiﬁed by the National Institute on Aging Intervention Test-
ing Program, to treat Alzheimer's disease.
Published by Elsevier Inc.1. Introduction
Rapamycin (also known as Sirolimus) is macrocyclic lactone pro-
duced by the bacterium Streptomyces hygroscopicus isolated from soil
samples from Easter Island. In 1975, Vezina et al. showed that cultures
of S. hygroscopicus inhibited the growth of fungi with no activity against
gram-positive and gram-negative bacteria and low toxicity in mice
(Vezina et al., 1975). Based on the initial studies, rapamycin was devel-
oped as an antifungal agent; however, because it was found to have im-
munosuppressive properties, this line of research was discontinued. In
1988, it was discovered that rapamycin had antirejection properties
without the side effects associated with other antirejection agents
(Camardo, 2003). This discovery led eventually to FDA approving in
1999 the use of rapamycin in combination with other immunosuppres-
sive agents to prevent the rejection of organs in transplant patients
(Camardo, 2003).
Amajor breakthrough occurred in 1994, when three groups showed
that rapamycin bound a speciﬁc protein, Target of Rapamycin (TOR)
(Cafferkey et al., 1994; Brown et al., 1994; Sabatini et al., 1994). TOR
was subsequently found to be the serine/threonine kinase that wasealth Sciences Center, ROCA/
lahoma City, OK 73104, USA.
rdson).the regulatory nexus in the response of eukaryote cells to nutrients,
growth factors, and cellular energy status. In mammals, TOR (mTOR)
forms twomajor complexes: mTORC1, which is inhibited by rapamycin
(Caron et al., 2010) and mTORC2, which has been reported to be in-
sensitive to rapamycin; however, recent data suggest that long term
rapamycin treatment might inhibit mTORC2 (Sarbassov et al., 2006).
The mTORC1 consists of mTOR, Raptor, mLST8, FKBP38, PRAS40, and
Deptor, and through speciﬁc binding of rapamycin to FKBP12, rapamycin
inhibits the activity ofmTORC1 leading to a decrease in protein synthesis,
increased autophagy and inhibition of cell growth (Stanfel et al., 2009).
2. Effect of rapamycin on longevity
The TOR signaling pathway is an attractive candidate to study with
respect to aging because it has the potential to affect a large number
of processes regulated by TOR signaling that could have a major effect
on an organism. In the early 2000s, investigators began studying the ef-
fect of TOR on lifespan of invertebrates. Mutations in TOR increased the
lifespan of yeast (Kaeberlein et al., 2005), Caenorhabditis elegans (Vellai
et al., 2003; Jia and Levine, 2007; Hansen et al., 2007), and Drosophila
(Kapahi et al., 2004). These data provided the ﬁrst evidence that in-
creased longevity could be achieved by reduced TOR signaling and sug-
gested that rapamycin, which inhibits TOR signaling, might increase
lifespan in other species, including mammals. In 2009, the National
52 A. Richardson et al. / Experimental Gerontology 68 (2015) 51–58Institute on Aging Interventions Testing Program reported that feeding
rapamycin tomice signiﬁcantly increased lifespan, bothmean andmax-
imum (Harrison et al., 2009). Not only was this the ﬁrst report to show
that a pharmacological agent could increase lifespan of a mammal, the
increase in lifespan was observed in both male and female mice on a
heterozygous background: (BALB/cByJ × C57BL/6J) F1 females crossed
to (C3H/HeJ × DBA/2J) F1 males, which is referred to as UM-HET3
mice. Thus, rapamycin's effect on lifespan is likely to apply to mice in
general, i.e., it is not unique to a speciﬁc inbred strain of mice. In addi-
tion, the increase in lifespan was replicated at three independent sites,
and the increase in lifespan was achieved when administered relatively
late in life (e.g., 19 months of age, which would be similar to ~65 years
of age in humans). This studywas selected by Science as oneof themajor
scientiﬁc breakthroughs in 2009 (Science 326, 1598–1607). The impor-
tance of showing that the increase in lifespan was increased when
rapamycin was administered late in life cannot be understated because
all previous experimental manipulations that increased the lifespan of
mammals (mice or rats) were implemented early in life. Thus, the
study by Harrison et al. (Harrison et al., 2009) provided the ﬁrst proof
of principle that a pharmacological agent could be developed to slow
down aging in humans, i.e., an anti-aging pill was not a dream but the-
oretically possible.
Since the initial publication in 2009, 15 reports have been published
on the effect of rapamycin on the lifespan of mice, and these studies are
listed in Table 1. The large number of studies on the lifespan of mice in
only ﬁve years is impressive and gives us an ability to generalize
about how rapamycin affects longevity. The current studies show
that rapamycin not only increases the lifespan of various strains of
‘normal’ laboratory mice, but also increases the lifespan of genetically
modiﬁed mouse models of various human diseases. In studies in which
male and femalemice have been compared, rapamycinwas found consis-
tently to have a greater effect on the lifespan of female mice. Of the 16
studies inwhich the lifespan of rapamycin treatedmice has been studied,
only two studies, both with transgenic mouse models of ALS (amyotro-
phic lateral sclerosis), show no increase in lifespan. Thus, the effect of
rapamycin on lifespan is very robust and reproducible in various strains
and geneticmodels ofmice. However, the studieswith the ALS transgenic
mice indicate that rapamycin's longevity effect may not be universal and
that some genotypes do not respond to rapamycin. It is also possible that
rapamycin might shorten the lifespan of some genetic models. A recentTable 1
Effect of rapamycin on lifespan of mice.
Reference Mouse
strain
Age initiated Increase in
lifespan
Control/wild type mice
Harrison et al. (2009) UM-HET3 19 months 9% M &14% F
Miller et al. (2011) UM-HET3 9 months 10% M &18% F
Anisimov et al. (2011) 129/Sv 2 months 10% F
Neff et al. (2013) C57BL/6 4, 13, & 20 months 11% M
Miller et al. (2014) UM-HET3 9 months 3–23% M & 16–26% F
Zhang et al. (2014) C57BL/6 19 months nc M & 6% F
Fok et al. (2014) C57BL/6 4 months 11% M & 16% F
Genetically modiﬁed
mice
Fujishita et al. (2008) ApcD716 6–14 weeks 140–220% M/F
Anisimov et al. (2010) HER-2 2 months 13% F
Comas et al. (2012) p53−/− 2 months 30% M
Ramos et al. (2012) Lmna−/− 3–4 weeks 23–57% M/F
Komarova et al. (2012) p53+/− ~5 months 10–28% M
Livi et al. (2013) Rb1+/− 8–10 week 14% M–9% F
Johnson et al. (2013) Ndufs4−/− ~20 days 25% M–38% F
Hasty et al. (2014) APCMin/+ 50 days 280–440% F
Zhang et al. (2011) G93A 64 days nc Sex?
Bhattacharya et al.
(2012)
H46R/H48Q 64 days nc M/F
The percent increase in lifespan (nc = no change) is shown for male (M) and female
(F) mice or a combination of male and female mice (M/F). The strain of mouse or the ge-
netic mouse model is given with the age that the rapamycin treatment was initiated.study by the National Institute on Aging Interventions Testing Program
compared the effect of various doses of rapamycin on the lifespan of
male and female UM-HET3 mice (Miller et al., 2014). Longevity was
shown to be dose-dependent from one-third to 3-fold the concentration
used initially by Harrison et al. (2009). Thus, the effect of rapamycin on
the lifespan of mice occurs over a broad dose range.
The observation that rapamycin increases lifespan (both mean and
maximum) in mice strongly suggests that rapamycin increases lifespan
by slowing down aging. In the past two years, several studies have ex-
amined the effect of rapamycin on various parameters of healthspan.
Currently, it appears that while rapamycin improves some measures
of physiological function that decline with age, other functions are not
altered by rapamycin. However to date, no physiological function that
changes with age is negatively altered by rapamycin (Richardson,
2013). One of the major consequences of aging, which leads to reduced
quality of life and increased medical costs seen in the elderly, is the oc-
currence of a wide variety of pathological conditions. Because animal
studies in which aging has been altered show a reduced/delayed inci-
dence of most age-related diseases, it is possible that rapamycin might
have a broad protection against age-related diseases in humans. The
current limited data support this possibility. For example, it is clear
that rapamycin has a dramatic effect on cancer in mice (Sharp and
Richardson, 2011), most likely because of its anti-growth and anti-
proliferation properties. In fact, it has even been argued that the life ex-
tension seen with rapamycin is due to its anti-cancer action rather than
an anti-aging action (Neff et al., 2013). In addition, several studies have
shown that rapamycin reduces atherosclerotic plaque formation in
mouse models of atherosclerosis (Pakala et al., 2005; Mueller et al.,
2008). Although rapamycin has been reported to improve various
motor-tasks in models of Huntington disease (Ravikumar et al., 2004)
and Parkinson's disease (Malagelada et al., 2010), therewas no informa-
tion on the effect of rapamycin on Alzheimer's disease before 2010 and
very little information on the effect of rapamycin on cognition. In fact,
the few early studies suggested that rapamycin might have a negative
effect onmemory, e.g., reduced long-termmemory facilitation and con-
solidation (Casadio et al., 1999; Tischmeyer et al., 2003) and long-term
plasticity in the brain (Tang et al., 2002). The focus of this report is to
describe the pioneering studies in which the effect of rapamycin on
Alzheimer's disease was tested in transgenic mice genetically manipu-
lated tomimic Alzheimer's disease (AD-Tgmice). In addition,we review
the current studies on the effect of rapamycin on cognition/memory in
other mouse models with cognitive impairment as well as ‘normal’ lab-
oratory mice.
3. Effect of rapamycin on Alzheimer's disease
3.1. Cognition/memory
The ﬁrst studies to test the effect of rapamycin on memory in AD-Tg
micewere initiated shortly after the 2009Nature publication on lifespan
and conducted independently by the laboratories of Oddo and Galvan.
They found, as shown in Fig. 1, that rapamycin prevented the loss of
memory/cognition in two different transgenic mouse models of AD
(Caccamo et al., 2010; Spilman et al., 2010). The 3xTg-AD mice used
by Oddo's laboratory harbors mutant forms of three human genes asso-
ciated with AD: amyloid protein precursor (APP), tau, and presinilin-1.
The 3xTg-AD mice are the only mouse model of AD that develops both
Aβ-containing plaques and tau-containing tangles. The 3xTg-AD mice
show signiﬁcant memory deﬁcits, which can be ﬁrst detected around
6 to 8months of age (Oddo et al., 2003). The hAPP(J20) used byGalvan's
laboratory overexpresses a minigene of APP carrying the Swedish and
Indiana FADmutations. The hAPP(J20)mice show an increase in soluble
Aβ levels in brain and synaptic deﬁcits starting at 3 months of age, age-
dependent AD-like decline in learning andmemory that can be detected
at seven months of age, and deposition of Aβ plaques starting at ~10
months of age that steadily increases with increasing age (Mucke
Fig. 1. Effect of Rapamycin on the Memory of AD-Tg Mice assessed by the Morris water maze. Graph A: data taken from Caccamo et al. (2010) for 3XTg-AD (AD-Tg) and non-transgenic
(Control)mice fed rapamycin (black bars) or a control diet (white bars) starting at 6months of age for 10weeks. GraphB: datawere taken fromSpilman et al. (2010) for hAPP(J20) (AD-Tg) and
non-transgenic (Control) mice fed rapamycin (black bars) or a control (white bars) diet starting at 4 months of age for 13 weeks.
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administration to young/adult AD-Tgmice for 10 to 13weeks prevented
the loss of cognition observed in the two AD-Tg mouse models studied
as measured by the Morris water maze. In fact, there was no signiﬁcant
difference between the control non-treated mice and the AD-Tg mice
treated with rapamycin. The dose of the encapsulated rapamycin, which
was delivered in the diet fed the AD-Tg mice, was the same as that used
in the studies showing rapamycin increased lifespan in UM-HET3
(Harrison et al., 2009) and C57BL/6 mice (Fok et al., 2014). It should
also be noted that rapamycin had no detrimental effect on memory/
cognition in the control mice as suggested in early studies. In fact,
under these experimental conditions, cognition in the control mice ap-
peared to be slightly, but not signiﬁcantly, improved.
While these studies show that rapamycin was able to prevent the
initial loss of memory in the AD-Tg mice, it was of interest to determine
whether rapamycinwould block ‘established’memory deﬁcits in symp-
tomatic animals that show cognitive deﬁcits, a stage in the progression
of AD-like disease that models mild cognitive impairment (MCI) in
humans. Galvan's laboratory showed that feeding rapamycin for 16
weeks to 7-month-old hAPP(J20) mice, which show AD-like cognitive
impairments, improved learning and restored memory to levels indis-
tinguishable from those of wild-type controls (Lin et al., 2013). These
data suggest that rapamycin may have the potential to treat cognitive
impairment at the earliest stage of AD.
Oddo's laboratory studied the effect of rapamycin treatment over the
lifespan of the AD-Tg mouse to determine if rapamycin could prevent
loss of memory. They showed that treating 2-month-old 3xTg-AD
mice with rapamycin for 16 months completely prevented the loss of
memory; the rapamycin treated 3xTg-AGmice at 18-months of age per-
formed as well as 18-month-old control mice (Majumder et al., 2011).
However, giving the 3xTg-AD mice rapamycin for 3 months starting at
15 months of age, an age at which mice show widespread plaques and
tangles and profound memory deﬁcits, had no effect on memory indi-
cating that rapamycin might have little effect on cognition if given at
later stages of AD. Interestingly, Galvan's laboratory recently found
that rapamycin treatment in young/adults could protect AD-Tg mice
from cognitive deﬁcits later in life. They found that hAPP(J20) mice fed
rapamycin for 16 weeks starting at 7 months of age, not only improved
cognition immediately after feeding rapamycin (Lin et al., 2013) but
was also sufﬁcient to maintain cognitive function late in life, such that
28-month-old hAPP(J20)mice given rapamycin for 16weeks at 7months
of age showed no detectable cognitive deﬁcits in a spatial novelty task
(Veronica Galvan personal communication). Therefore, the current data
with AD-Tg mice show that the loss of memory can be prevented by
rapamycin and that rapamycin-treatment can restore memory if im-
plemented shortly after the onset of memory impairment; however,rapamycin may have little effect when given at late stages of the dis-
ease after overt plaque and tangle deposition.
3.2. Plaques, tangles, and autophagy
One of the hallmark features that characterize AD is the accumula-
tion of Aβ-containing plaques and tau-containing tangles, which are be-
lieved to play a major role in the decline in memory. As shown in
Fig. 2(A–F), Oddo's laboratory found that rapamycin treatment reduced
the accumulation of Aβ levels and ﬁbrillar aggregates of Aβ ap-
proximately 40 to 50% in the 3XAD-Tg mice fed rapamycin for 16
months (Majumder et al., 2011). In addition, rapamycin reduced
tau-aggregation as measured by tau phosphorylation (Fig. 2G, H).
Microglia activation, which is an invariable feature of AD pathology, was
also observed to be dramatically reduced in the rapamycin treated AD-
Tgmice (Fig. 2I, J). Consistentwith these observations, Galvan's laboratory
has also documented that rapamycin reduced levels of Aβ in the brains of
hAPP(J20) mice after a few months (Spilman et al., 2010) and amyloid
plaques at later stages of the AD-like disease (Lin et al., 2013).
Because rapamycin is known to induce autophagy and because au-
tophagy is the primary pathway cells use to degrade protein aggregates,
both Galvan's and Oddo's laboratories studied the role of autophagy in
the reduction of plaques and tangles in the brains of AD-Tg mice. They
showed that markers of autophagy were induced in the brains of
hAPP(J20) mice (Spilman et al., 2010) and 3XTg-AD mice (Caccamo
et al., 2010). In addition, Oddo's laboratory showed that rapamycin
treated mice show a greater localization of Aβ in lysosomes (60% vs
20%), suggesting a more active degradation of these peptides after
rapamycin treatment. Oddo's laboratory went on to show that the de-
crease in Aβ levels induced by rapamycin in cells expressing Aβ could
be prevented by blocking autophagy. More recently, Oddo's laboratory
showed that rapamycin administration decreased tau pathology in a
mouse model of tauopathies, indicating that rapamycin might be beneﬁ-
cial not only for AD but also for other tauopathies (Caccamo et al., 2013).
Therefore, it appears that the induction of autophagy by rapamycin plays
amajor role in the decrease in the accumulation of plaques and tangles in
the brains of the AD-Tg mice and possibly the improvement in memory.
Oddo's laboratory also has taken a genetic approach to determine if
the effect of rapamycin on cognition and plaque accumulation occurred
through mTOR. Although rapamycin is an mTOR inhibitor, there is
growing evidence that it may also have effects independent of mTOR
(Malagelada et al., 2010; Thoreen and Sabatini, 2009). For example,
rapamycin suppresses mTOR-dependent translation of some classes of
mRNAs but not others (Choo et al., 2008). In additional, rapamycin
binds to L-type voltage-dependent Ca2+ channels, and it is thought
that this binding may mediate some of the neuroprotective properties
C D
E F
G H
I J
A B
Control +Rapamycin
Fig. 2. Effect of rapamycin on plaques and tangles in brains of 3XTg-ADmice. The levels of
Aβ42 in whole brain (A, B) or hippocampus (C, D), ﬁbrillar aggregates of Aβ (E, F), tau pa-
thology asmeasured by hyperphosphorylation at Ser212 and Thr214 (G, H), andmicroglia
activation (I, J) weremeasured in 2-month-oldmice fed rapamycin or a control diet for 16
months.
Data taken from Majumder et al. (2011).
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moved one copy of the mTOR gene in the brains of the Tg2576 mice, a
widely used animal model of AD. They found that genetic suppression
of mTOR signaling reduced Aβ deposits and rescued memory deﬁcits
(Caccamo et al., 2014), mimicking the rapamycin-mediated improve-
ments. These data strongly suggest that the rapamycin effects on AD-
like pathology in mice are mediated through mTOR signaling.
3.3. Cerebral blood ﬂow (CBF) and vascular function
In addition to the accumulation of plaques and tangles, vascular dys-
function is a phenotype of AD (Nagata et al., 2000). Using small animal
imaging, Galvan's laboratory in collaborationwith Ai-Ling Lin employedimaging techniques similar to those used in humans to determine the
effect of rapamycin on vascular function (Lin et al., 2013). As shown in
Fig. 3(A, B), they found that CBF was restored to wild type levels when
the hAPP(J20)micewere treatedwith rapamycin for 16weeks. The res-
toration of CBF in hAPP(J20) mice was not due to changes in glucose
metabolism but appeared to arise from changes in vascular density as
shown in Fig. 3(C, D); rapamycin restored vascular density in the brains
of hAPP(J20)mice to the levels found in the brains of control, untreated
hAPP(J20). Ai-Ling Lin has also found that rapamycin improves CBF in
old rats, LDL-receptor mice fed a high-fat diet, and APOE4 transgenic
mice (personal communication); thus, rapamycin's ability to restore
vascular function in the brain is not limited to AD.
The data obtained by Lin et al. (2013) also indicated that rapamycin
acts acutely as an NO-dependent vasodilator, as had been suggested by
Cheng et al. (2008). Therefore, they propose that rapamycin's activation
of nitric oxide synthase is critical for the restoration of CBF in hAPP(J20)
mice. Because the deposition of Aβ in the brain vasculature has been
shown to cause microvessel disruption (Zlokovic, 2011), it is possible
that the improvement in vascularization in rapamycin-treated treated
AD-Tg mice is accompanied by decreased Aβ deposition within brain
vasculature. Lin et al. (Lin et al., 2013)measured the amount of Aβ asso-
ciated with brain blood vessels in rapamycin-treated and untreated
hAPP(J20) mice. Fig. 3(E, F) shows that the Aβ associated with brain
was signiﬁcantly reduced in rapamycin-treated hAPP(J20) mice, which
was correlated to reduced microhemorrhages (see Fig. 3M, N in (Lin
et al., 2013)).
In summary, data generated over the past four years show that
rapamycin can prevent, and possibly reverse, the complete ADphenotype
observed in transgenic mouse models of AD, e.g., memory is improved,
the accumulation of Aβ- and tau-aggregates is reduced, microglia activa-
tion is prevented, and CFB and brain vascular density are restored. Based
on the current data, we propose that rapamycin prevents AD by acting on
several pathways that can potentially lead to cognitive impairment as
shown in Fig. 4. First, rapamycin increases the clearance of Aβby restoring
vascular integrity and CBF, and second, rapamycin increases the deg-
radation of Aβ and tau aggregates by inducing autophagy, thereby
counteracting the hyperactivation of mTOR that is observed in the
brains of AD-Tg mice and patients (Oddo, 2012; Sun et al., 2014).
4. Effect of rapamycin onmousemodels that are cognitively impaired
Studies over the past 5 years have shown that rapamycin can prevent
cognitive impairment that occurs in a number of disorders/conditions
that does not involve the accumulation of plaques/tangles. One of the
ﬁrst studies showing the beneﬁts of rapamycin treatment on cognition
was reported for mice heterozygous for Tsc2 (tuberous sclerosis protein
2). Tsc1 and Tsc2 form a protein-complex that has tumor suppressor ac-
tivity and also inhibitsmTOR activity. Mutations in these two genes result
in hyperactivation of mTOR that is characterized by hamartomas, benign
growth of tumors in various organs. However, mutations in these genes
also produce changes in the central nervous system separate from
tumor growth. Ehninger et al. (2008) showed that Tsc2+/−mice have def-
icits in learning and memory in the absence of neuropathology and sei-
zures, and rapamycin treatment of these mice rescued the behavioral
deﬁcits in the Tsc2+/−mice, including the impairment in memory. Since
this report, rapamycin has been shown to prevent/restore the loss of
memory arising from a number of other disorders/manipulations, which
are associated with the hyperactivation of mTOR, and these studies are
listed in Table 2. These disorders/conditions range from drug/alcohol
treatment to induce seizures, to genetic manipulations that result in
autism-like phenotypes. In addition, Erlich et al. (2007) reported that
treating mice with rapamycin after brain trauma enhances the recovery
of the brain from injury. Thus, the current literature shows that rapamycin
has a broad range of effects on the central nervous system. This should not
be surprising because components of the mTOR pathway are widely
expressed in the central nervous system, especially Tsc1 and 2, which
         Control +Rapamycin
A B
C D
E F
Fig. 3. Effect of rapamycin on CBF, vascularization, and cerebral amyloid angiopathy in hAPP(J20) mice. Panels A and B show CBF in various brain regions with brighter colors indicating
increased blood ﬂow. Panels C and D showmagnetic resonance angiography images of brains showing vasculature with the arrows pointing to regions of the brain where rapamycin re-
stored vascular density. Panels E and F showAβ (shown in red) associatedwith brain blood vessels (shown in green). The datawere taken from Lin et al. (2013) for 7-month-oldmice fed
rapamycin or a control diet for 16 weeks.
55A. Richardson et al. / Experimental Gerontology 68 (2015) 51–58are highly abundant in the adult central nervous system and play amajor
role in regulating mTOR activity (Ehninger and Silva, 2011).
5. Effect of rapamycin on cognition and behavior of ‘normal’ labora-
tory mice
The ﬁrst study to show that rapamycin increased cognition of ‘nor-
mal’ laboratory mice was conducted by Oddo's laboratory in 2012
(Majumder et al., 2012). They found that 18-month-old mice treated
with rapamycin for 16 months showed signiﬁcantly improved spatial
memory on the Morris water maze compared to the mice fed a control
diet. Subsequently, Galvan's laboratory (Halloran et al., 2012) and NeffVascular
Dysfunction
CBF
Vascular
Density
(hy
Aβ
Clearance
Rapamycin
Fig. 4.Diagram showing the protective effect of rapamycin in AD using the ‘two-hit’ process des
Aβ through the restoration of vascular integrity. Rapamycin also blocks the second ‘hit’ by indu
activation of mTOR, which occurs in the brains of AD-Tg mice and patients.et al. (Neff et al., 2013) also showed that rapamycin improved spatial
memory of mice on the Morris water maze. Fig. 5 compares the Morris
water maze data generated by these three groups. In addition, Galvan's
group showed that rapamycin restored the memory of old mice on a
passive avoidance task.Majumder et al. (2012) found that the improve-
ment in cognation observed with rapamycin was associated with
decreased brain levels of the pro-inﬂammatory cytokine, IL-1β, and in-
creasedNMDA signaling; both have been shown to affect brain function.
It should be noted that Erlich et al. (Erlich et al., 2007) found that
rapamycin reduced inﬂammation as shown by decreased numbers of
activatedmicrogila in their brain injury model, and several studies sug-
gest that rapamycin reduces inﬂammation in various tissues (ChenAccumulation 
of Aβ
Cognitive
Impairment
in AD
Reduced
Autophagy
peracvaon of mTOR)
cribed by Zlokovic (2011). Rapamycin prevents the ‘ﬁrst hit’ by increasing the clearance of
cing autophagy preventing the accumulation of Aβ in the brain counteracting the hyper-
Table 2
List of neurological disorders improved by rapamycin treatment.
Disorder/condition Rapamycin treatment Effect of rapamycin Reference
Head injury 4 h after head trauma Greater improvement of markers of neurobehavioral function Erlich et al. (2007)
Tsc2+/−Mice Treated 3 h to 5 days continuously
before assays.
Corrects deﬁcits in memory/learning (Morris water maze and the 8-arm
radial maze) and contextual discrimination.
Ehninger et al. (2008)
THC-cannabinoid treatment Pre-treatment for 5 days Prevented decline in performance on the novel object recognition test Puighermanal et al.
(2009)
Alcohol addiction 1 dose Attenuates conditioned preference to alcohol, e.g., decreased binge
drinking and motivation to consume alcohol
Neasta et al. (2010)
Deletion of Tsc1 in the cerebellar
Purkinje cells
Started at P7 Prevented deﬁcits in cognition on the water T-maze, pathological
phenotypes of autism in the brain, and autistic-like behavior
Tsai et al. (2012)
Pilocarpine-induced seizures Post-treatment every other day for
8 days
Restoration of cognation as measured on the Morris water maze and the
novel object recognition test
Brewster et al. (2013)
Disc1 knockdown in dentate granule
neurons
Treatment 5–13 days after retroviral
injection
Reversed deﬁcits in cognition (object-place recognition task) as well
anxiety phenotype (elevated plus maze)
Zhou et al. (2013)
Reduced
Inﬂammaon
Increased NOS
Acvaon
56 A. Richardson et al. / Experimental Gerontology 68 (2015) 51–58et al., 2009; Bonegio et al., 2005; Dubois et al., 2003). Therefore, some of
the beneﬁts arising from rapamycin treatment might occur through
rapamycin's anti-inﬂammatory actions.
In addition to studying the effect of rapamycin on memory, Galvan's
laboratory studied the effect of rapamycin on non-cognitive components
of behavior, speciﬁcally anxiety- and depressive-like behaviors (Halloran
et al., 2012). They found that 4-month-old mice treated with rapamycin
for 16weeks showed reduced anxiety-like behavior, e.g., reduced thigmo-
taxis (swimming in close proximity to the pool wall) and reduced aver-
sion to open spaces using an elevated plus maze. Rapamycin also was
found to reduce depressive-like behavior, e.g., ﬂoating during training
phase of the Morris water maze and reduced time spent immobile on
the tail suspension test. Similar effects of rapamycin on behavior have
been reported for genetically modiﬁed mice that show autistic-like be-
havior. Mice with mutations in Tsc2 or Disc1 genes, show increased anxi-
ety, hyperexcitability, abnormal social interaction, repetitive behavior and
vocalizations, all of which are attenuated by rapamycin treatment (Tsai
et al., 2012; Zhou et al., 2013). Recently, Kolosova et al. (2013) reported
that rapamycin treatment decreased anxiety and improved locomotor
and exploratory behavior in senescence-accelerated OXYS rats. In addi-
tion, Neasta et al. (2010) showed that rapamycin attenuates the condi-
tioned preference of rats and mice to alcohol. Therefore, rapamycin
affects a wide variety of cognitive and non-cognitive types of behavior
in rodents. Galvan's laboratory showed that the changes in anxiety- and
depressive-like behavior were correlated with increased levels of dopa-
mine and dopamine metabolites in the midbrain.
6. Conclusion
Research over the past four years has shown that rapamycin can have
quite profound effects on the central nervous system of mice, resulting inFig. 5. Effect of rapamycin on memory of 'normal' laboratory mice. Mice were fed
rapamycin (black bars) or a control diet (white bars) for various lengths of time and cog-
nitive performance measured by the Morris water maze. The right graph is 2-month-old
mice fed rapamycin for 16 months (data taken from Majumder et al., 2012). The middle
graph is 4-month-old mice fed rapamycin for 16 weeks (data taken from Halloran et al.
(2012)). The right graph is 4-month-old mice fed rapamycin for 11 months.
Data taken from Neff et al., 2013).both improved memory and changes in behavior, e.g., anxiety and de-
pression. As shown in Fig. 6, the changes in behavior and cognition ob-
served in mice could arise through a number of pathways that have
been reported to be altered by rapamycin. Many of these pathways
could also play an important role in preventing the progression of
Alzheimer's disease.
The studies from Oddo's and Galvan's laboratories show quite con-
vincingly that rapamycin given to mice at a dose shown to increase
lifespan and delay many aging phenotypes and pathologies prevented,
and may have restored, the loss in cognition observed in two different
transgenic mouse models of Alzheimer's disease. As noted in a recent
review, despite over a thousand clinical trials related to AD, only ﬁve
drugs are currently approved for treatment of the disease (Cavanaugh
et al., 2014); unfortunately, these ﬁve drugs have no effect on the pro-
gression of AD. Also disappointing has been the inability to translate
to humans therapies that prevent deﬁcits in cognition in AD-Tg mouse
models. It has been argued that the lack of translation from mice to
humans is due to species differences in brain structure and complexity.
It is also possible that the types of mousemodels used do not accurately
mimic sporadic AD, which accounts for over 95% of the cases of AD. For
example, all the AD transgenic mouse models overexpress in the brain
various human genes containing mutations associated with familial
AD. These AD-Tg mice show a loss of cognition and accumulation of
Aβ aggregates early in life, comparable to ~20-year-old human. There-
fore, the AD-Tg mice currently used to study AD may not be goodIncreased
Autophagy
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Vascular
Density
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Nervous
System
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Fig. 6. Diagram showing pathways reported to change with rapamycin treatment that
could impact the changes observed in behavior and cognition observed in laboratory
rodents.
57A. Richardson et al. / Experimental Gerontology 68 (2015) 51–58models of sporadic AD,which occurs late in life (after 65 years of age). In
addition, most of the recent therapies developed to treat AD have
focused on reducing the accumulation of Aβ aggregates, either by
preventing the processing of Aβ using inhibitors of γ- or β-secretases
or using immunization strategies to remove Aβ deposits.While plaques
and tangles are correlatively linked to disease symptoms of AD, they
may not be causal or key in the mechanism initiating the disease.
We propose that rapamycin has greater likelihood of successfully
treating AD than previous therapies studied for three reasons. First,
rapamycin appears to have a major effect on aging in rodents, and age
is the single greatest risk factor for AD. In fact, the initial study showed
that rapamycin was effective in increasing lifespan when implemented
late in life (Harrison et al., 2009). Therefore, altering pathways funda-
mental to agingwould be a novel strategy for treating AD, and this strat-
egy is possible now that we have pharmacological intervention into
aging with rapamycin that affects a large number of age-related dis-
eases and pathologies in mice (Richardson, 2013). Second, rapamycin
appears to have a very broad effect on the central nervous system. It
not only reduces the accumulation of both Aβ and tau-containing
aggregates, it also improves and restores vascular function and CBF as
well as reducing inﬂammation. Third, rapamycin has an effect on both
cognition and behavior in mouse models other than AD-Tg mice,
i.e., rapamycin appears to have a very broad effect on the central ner-
vous system. Thus, we predict that rapamycin will potentially be suc-
cessful in treating sporadic AD patients because of rapamycin's anti-
aging properties, which affect a wide range of pathways (not just Aβ
aggregation) thatmight be involved in the initiation and/or progression
of sporadic AD, e.g., such pathways as proteostasis, inﬂammation, vascu-
lar dysfunction, etc.
One major advantage to using rapamycin (or its derivatives, called
rapalogues) to treat AD is that it has been approved by the FDA since
1999 for various uses in humans. Therefore, the toxicity proﬁles of
rapamycin and its rapalogues are well characterized (Soefje et al.,
2011). The use of rapamycin and rapalogues in treatment of AD is also
attractive because these compounds have been given to cancer patients
for relatively long periods of time with little change in the quality of life
(Mita and Mita, 2011). In fact, a pilot study by Lang et al. (Lang et al.,
2009) reported that Everolimus, a derivative of rapamycin, affected cog-
nition and depression in humans in a way that is similar to what has
been observed in mice. In the study, nine cardiac transplant patients
(66±6 years of age)whohad initially received a standard immunosup-
pression regimen of calcineurin inhibitors were followed when they
were switched to Everolimus. Four weeks after Everolimus treatment,
signiﬁcant improvements were observed inmemory (Wechsler Memo-
ry Scale-Revised), depression (Beck Depression Inventory), and execu-
tive function (Trail Making Tests A and B).Acknowledgments
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